HK Stock Market Move | SIHUAN PHARM(00460) rose more than 12% in the morning session. SIHUAN PHARM's clinical research results on the freeze-dried beauty space "Meiyan" were published in the international SCI journal.

SIHUAN PHARM(00460) rose more than 12% in early trading, and as of the time of writing, it has risen by 8.33% to HKD 0.91, with a trading volume of HKD 51.6124 million. On the news front, recently, SIHUAN PHARM led a clinical study on frozen beauty in collaboration with several public hospitals and top medical beauty institutions nationwide, achieving significant academic results. The related research paper was officially published in the international authoritative SCI journal "Journal of Cosmetic Dermatology". This achievement not only provided high-quality clinical evidence for frozen beauty (the first compliant facial dynamic element in China containing L-peptide), but also signaled its international academic recognition in improving skin quality. China Securities Co., Ltd. previously pointed out that by 2026, as the core growth engine, the core blockbuster product Le Te Pao is expected to further increase sales, while new products such as Tongyan Needle, Girl Needle, and dynamic elements in the regenerative and hyaluronic acid categories, which will be launched on 25H2, will have their first complete sales year. It is expected that through combination sales, the new products will drive rapid sales growth; on this basis, with the continuous improvement of the company's product matrix and the scale effect of channels, it is expected to drive the continuous improvement of the profit capability of the medical beauty sector.